KPTI
Karyopharm Therapeutics Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 3 ▼ 1 insider sell $10.2K at $6.30
- Mar 2 ▼ 5 insiders sell $245.7K at $9.41
- Apr 21 ▼ 1 insider sell $4.0K at $8.94
- May 14 ▼ 6 insiders sell $34.7K at $9.50
- Jul 28 ▼ 1 insider sell $1.3K at $7.10
- Aug 14 ▼ Short interest jumps 27.6% to 9.64M
- Sep 1 ▼ 1 insider sell $38.38 at $2.02
- Oct 1 ▼ 1 insider sell $449.82 at $1.19
- Oct 16 ▼ 1 insider sell $1.6K at $0.3440
- Nov 2 Trading halt: Trading Halt: KPTI · T1 (News Pending)
- Nov 2 ▼ Rodman & Renshaw downgrades
- Nov 5 ▼ Karyopharm Therapeutics received a delisting notice from Nasdaq foll…
Signal stack
Where each data set points today.
- InsidersBEARISH
7 insiders sold $298.2K.
- InstitutionsBULLISH
Q3 2026: 7 added (0 new), 2 trimmed or exited.
- AnalystsBULLISH
9 of 11 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$1.457 → −$1.050 over 90 days. 1 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +13.3% to 8.23M shares. 1.1 days to cover, ≈36.3% of shares.
- TrendDOWNTREND
97% below its 50-day average. New closing low $0.0170 on Nov 10.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 6.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | DOUBLED | $1.2M |
| FMR LLC | DOUBLED | $293.2K |
| SIMPLEX TRADING, LLC | DOUBLED | $85.2K |
| Nuveen, LLC | ADD | $80.0K |
| RHUMBLINE ADVISERS | ADD | $37.5K |
| BARCLAYS PLC | NEAR_EXIT | $35.1K |
| SEI INVESTMENTS CO | ADD | $26.1K |
| Russell Investments Group, Ltd. | DOUBLED | $8.3K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analystsPrice is below the lowest target. Median implies +27900%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 2, 2026 | Rodman & Renshaw DOWNGRADE | Neutral |
| Jul 31, 2026 | Piper Sandler MAINTAIN | Overweight |
| Jul 31, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Abate Kristin Chief Accounting Officer Oct 16, 2026 | SELL | $1.6K |
Abate Kristin Chief Accounting Officer Oct 1, 2026 | SELL | $449.82 |
Abate Kristin Chief Accounting Officer Sep 1, 2026 | SELL | $38.38 |
Poulton Stuart EVP, Chief Development Officer Jul 28, 2026 | SELL | $1.3K |
Greene Barry E Director May 21, 2026 | AWARD | 15,508 sh |
Su Zhen Director May 21, 2026 | AWARD | 15,508 sh |
Schor Chen Director May 21, 2026 | AWARD | 15,508 sh |
Oliger Christy J. Director May 21, 2026 | AWARD | 15,508 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.05 | -$1.05–-$1.05 | +14.4% | $33.1M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | -$4.10 | -$4.10–-$4.10 | +22.1% | $134.4M |
| Next FY | -$1.72 | -$2.50–-$0.94 | +27.9% | $159.9M |
Washington
Short side
FINRA· Oct 30, 2026| Nov 2, 2026 | Resumption Scheduled | Resumed |
| Jul 30, 2026 | Resumption Scheduled | Resumed |
SecBot reports
30 filings · 1 bullish · 14 bearish · 2 mixed · 13 neutral- NEUTRAL SC 13G/ANov 13, 2026
Affinity Asset Advisors and Michael Cho filed an amended Schedule 13G disclosing a new passive…
Monitor whether Affinity Asset Advisors converts this passive 13G to an active 13D, which would signal a shift in intent. The warrant-based position and beneficial ownership limitation suggest a…
- BEARISH NT 10-QNov 13, 2026
Karyopharm Therapeutics filed an NT 10-Q stating it cannot timely file its Q3 2026 10-Q due to the…
The filing confirms that common stock has no expected recovery under the prepackaged plan. Monitor the bankruptcy court docket for approval of the plan and any competing bids; the stock is now…
- NEUTRAL SC 13G/ANov 12, 2026
Adage Capital Management filed an amended Schedule 13G disclosing a beneficial ownership of…
Monitor for any future conversion to a 13D filing or additional stake increases, which could signal a shift from passive to activist intent. The large increase in a micro-cap stock warrants attention.
- NEUTRAL SC 13G/ANov 9, 2026
Goldman Sachs filed an amended Schedule 13G disclosing a beneficial ownership of 203,129 shares…
Monitor for any further amendments or conversion to a 13D if Goldman Sachs increases its stake or changes investment intent. The current passive stake is minimal and unlikely to drive stock movement.
All KPTI filing & press-release reports (30)
- SC 13G/A reportNov 13, 2026
- NT 10-Q reportNov 13, 2026
- SC 13G/A reportNov 12, 2026
- SC 13G/A reportNov 9, 2026
- 8-K reportNov 5, 2026
- 8-K reportNov 2, 2026
- 8-K reportNov 2, 2026
- SC 13G/A reportOct 28, 2026
- 8-K reportOct 22, 2026
- 8-K reportOct 14, 2026
- SC 13G/A reportOct 8, 2026
- SC 13G/A reportSep 25, 2026
- SC 13G/A reportSep 25, 2026
- 8-K reportSep 11, 2026
- 8-K reportAug 31, 2026
- 8-K reportAug 13, 2026
- PRESS-RELEASE reportAug 10, 2026
- 8-K reportJul 31, 2026
- 8-K reportJul 17, 2026
- CLUSTER reportMay 15, 2026
- CLUSTER reportMay 15, 2026
- CLUSTER reportMay 15, 2026
- CLUSTER reportMay 15, 2026
- CLUSTER reportMay 15, 2026
- EFFECT reportMay 15, 2026
- 8-K reportMay 14, 2026
- S-3 reportMay 4, 2026
- S-3 reportMay 4, 2026
- CLUSTER reportMar 2, 2026
- 8-K reportMar 3, 2026